Dermavant Sciences Ltd (DRMT_old)

Currency in USD
0.02
0.00(0.00%)
Closed·
Showing Dermavant Sciences historical data. For real-time data please try another search
Day's Range
0.000.02
52 wk Range
0.000.02
Key Statistics
Prev. Close
0.02
Open
0.02
Day's Range
-
52 wk Range
0-0
Volume
-
Average Volume (3m)
0
1-Year Change
-
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Dermavant Sciences Ltd Company Profile

Dermavant Sciences Ltd., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. The company’s lead product candidate is Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent topical cream that is in Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Its product candidates in Phase I clinical trials include Cerdulatinib (DMVT-505), a dual inhibitor of the Janus kinase and spleen tyrosine kinase pathways for the treatment of vitiligo as well as other inflammatory skin conditions, such as atopic dermatitis, and Oxybutynin/Pilocarpine (DMVT-504), an investigational oral therapy for the treatment of primary focal hyperhidrosis. The company’s product candidates in the preclinical stage are DMVT-503, a topical DGAT1 inhibitor for the treatment of acne vulgaris, and DMVT-501 (lotamilast), a topical phosphodiesterase type 4 inhibitor that is used as a potential treatment option for atopic dermatitis. Dermavant Sciences Ltd. was formerly known as Roivant Dermatology Ltd. and changed its name to Dermavant Sciences Ltd. in June 2016. The company was founded in 2016 and is based in London, United Kingdom. Dermavant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd. As of October 28, 2024, Dermavant Sciences Ltd. operates as a subsidiary of Organon & Co..

Employees
48

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DRMT_old Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.